Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Rudi, Tatjana [VerfasserIn]   i
 Zietemann, Vera [VerfasserIn]   i
 Meißner, Yvette [VerfasserIn]   i
 Zink-Lorenz, Angela Maria [VerfasserIn]   i
 Krause, Andreas [VerfasserIn]   i
 Lorenz, Hanns-Martin [VerfasserIn]   i
 Kneitz, Christian [VerfasserIn]   i
 Schaefer, Martin Alexander Peter [VerfasserIn]   i
 Strangfeld, Anja Maria [VerfasserIn]   i
Titel:Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease
Titelzusatz:a cohort study from the German RABBIT register
Verf.angabe:Tatjana Rudi, Vera Zietemann, Yvette Meissner, Angela Zink, Andreas Krause, Hanns-Martin Lorenz, Christian Kneitz, Martin Schaefer, Anja Strangfeld
E-Jahr:2024
Jahr:April 4, 2024
Umfang:13 S.
Illustrationen:Illustrationen
Fussnoten:Gesehen am 21.10.2024
Titel Quelle:Enthalten in: RMD Open
Ort Quelle:London : BMJ Publishing Group, 2015
Jahr Quelle:2024
Band/Heft Quelle:10(2024), 2, Artikel-ID e003789, Seite 1-13
ISSN Quelle:2056-5933
Abstract:Objectives To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD). - Methods Patients with RA-ILD were selected from the biologics register Rheumatoid Arthritis: Observation of Biologic Therapy (RABBIT). Using time-varying Cox regression, the association between clinical measures and mortality was investigated. The impact of DMARDs was analysed by (1) Cox regression considering cumulative exposure (ie, treatment months divided by total months) and (2) time-varying Cox regression as main approach (treatment exposures at monthly level). - Results Out of 15 566 participants, 381 were identified as RA-ILD cases with 1258 person-years of observation and 2.6 years median length of follow-up. Ninety-seven patients (25.5%) died and 34 (35.1%) of these were not receiving DMARD therapy at the time of death. Higher inflammatory biomarkers but not swollen and tender joint count were significantly associated with mortality. Compared with tumour necrosis factor inhibitors (TNFi), non-TNFi biologic DMARDs (bDMARDs) exhibited adjusted HRs (aHRs) for mortality below 1, lacking statistical significance. This finding was stable in various sensitivity analyses. Joint aHR for non-TNFi biologics and JAKi versus TNFi was 0.56 (95% CI 0.33 to 0.97). Receiving no DMARD treatment was associated with a twofold higher mortality risk compared with receiving any DMARD treatment, aHR 2.03 (95% CI 1.23 to 3.35). - Conclusions Inflammatory biomarkers and absence of DMARD treatment were associated with increased risk of mortality in patients with RA-ILD. Non-TNFi bDMARDs may confer enhanced therapeutic benefits in patients with RA-ILD.
DOI:doi:10.1136/rmdopen-2023-003789
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1136/rmdopen-2023-003789
 kostenfrei: Volltext: https://rmdopen.bmj.com/content/10/2/e003789
 DOI: https://doi.org/10.1136/rmdopen-2023-003789
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:arthritis, rheumatoid
 biological therapy
 inflammation
 risk factors
 tumor necrosis factor inhibitors
K10plus-PPN:190634969X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69263939   QR-Code
zum Seitenanfang